预防性胸导管结扎在微创McKeown食管癌切除术中的短期与长期结局:倾向性评分匹配分析
该研究回顾性分析600例接受胸腔镜-腹腔镜McKeown食管癌切除术的患者,其中559例预防性结扎胸导管、41例未结扎;倾向性评分匹配后比较显示,结扎组术后乳糜胸发生率显著低于保留组(1.3% vs 12.2%,P=0.001),且两组中位生存期与5年生存率无显著差异。
要点
- 预防性胸导管结扎可显著降低微创McKeown食管癌切除术后乳糜胸发生率。
- 结扎胸导管对长期生存无不利影响,中位生存期与5年生存率组间相当。
- 该操作为安全有效的预防措施,但需结合患者个体情况权衡。
核心结论
- 在微创McKeown食管癌切除术中常规结扎胸导管是预防术后乳糜胸的有效且安全的方法,且对长期生存无不利影响。
研究设计与样本
- 回顾性队列研究,纳入2009年9月至2018年7月在大坪医院胸外科连续接受胸腔镜-腹腔镜McKeown食管癌切除术的600例胸段食管癌患者。
- 其中559例接受预防性胸导管结扎,41例未结扎;采用倾向性评分匹配改善组间可比性,匹配后保留组40例、结扎组134例。
- 使用Log-rank检验评估组间生存差异。
主要发现
- 术后乳糜胸在保留组发生5例、结扎组发生7例,发生率分别为12.2%与1.3%,差异有统计学意义(P=0.001)。
- 匹配前保留组中位年龄57.78岁(范围37-76),结扎组62.75岁(范围39-87);保留组肿瘤位于中段胸段食管及T3期患者比例更高(82.9% vs 55.6%,70.7% vs 45.6%)。
- 匹配后两组在年龄、肿瘤位置和T分期方面无显著差异。
- 保留组与结扎组中位生存时间分别为69.5个月(95%CI 54.6-84.3)和65.2个月(95%CI 56.3-74.1),P=0.977。
- 两组5年生存率相当(54.9% vs 54.4%,P=0.977)。
临床怎么用
- 在微创McKeown食管癌切除术中可考虑常规行预防性胸导管结扎,以降低术后乳糜胸风险,且不牺牲长期生存。
局限性
- 本研究为单中心回顾性分析,非结扎组样本量较小(41例),倾向性评分匹配后保留组仅40例,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chylothorax remains a challenging and potentially life-threatening postoperative complication after minimally invasive esophagectomy (MIE). The effect of intraoperative prophylactic thoracic duct ligation on preventing postoperative chylothorax still remains controversial. Moreover, the potential impact of thoracic duct ligation on long-term outcome after MIE has not been well established. METHODS: From September 2009 to July 2018, a total of 600 consecutive patients suffering from thoracic esophageal cancer who underwent thoracoscopic-laparoscopic McKeown esophagectomy in the Department of Thoracic surgery at Daping hospital were eligible. Among them, 559 patients received esophagectomy with preventive thoracic duct ligation and 41 patients did not. Propensity score matching (PSM) was performed to improve comparability between the two groups. Log-rank test was used to assess the survival differences between groups. RESULTS: Postoperative chylothorax occurred in five patients in the preservation group (PG) and in seven patients in the ligation group (LG) (12.2% vs. 1.3%, P = 0.001). The median age of the patients in the preservation group (PG) was 57.78 (range, 37-76) years, while the median age in the ligation group (LG) was 62.75 (range, 39-87) years. The PG had more patients with tumor located in middle thoracic esophagus and stage T3 than LG, 82.9% vs. 55.6%, 70.7% vs. 45.6%, respectively. After PSM (40 matched patients in PG and 134 in LG), there was no significant between-group difference with respect to age, tumor location, and T stage. The median survival times for patients in the PG and LG were 69.5 months (95% interval confidence, CI 54.6-84.3) and 65.2 months (95% CI 56.3-74.1), respectively (P = 0.977). The 5-year survival rates were comparable between PG and LG (54.9% vs. 54.4%, P = 0.977). CONCLUSION: On the basis of the present results, routine thoracic duct ligation during minimally invasive McKeown esophagectomy for cancer is an effective and safe method for prevention of postoperative chylothorax, and does not exert unfavourable effect on long-term survival.
引用
- Bao T, Wang YJ, Li KK, et al. Short- and long-term outcomes of prophylactic thoracic duct ligation during thoracoscopic-laparoscopic McKeown esophagectomy for cancer: a propensity score matching analysis. Surg Endosc. 2019. PMID: 31828499. doi:10.1007/s00464-019-07297-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。